BIIB · Biogen
AI read · Good for BIIB
The AI's read
These findings add support for LEQEMBI's long-term use in early Alzheimer's disease. Continued treatment by most patients and no new safety signals during subcutaneous maintenance strengthen that case. The comparison used a matched natural history group, so it does not prove the same result for every patient.